WallStSmart

Api Group Corp (APG)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 47% more annual revenue ($12.00B vs $8.17B). VRTX leads profitability with a 32.9% profit margin vs 4.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).

APG

Hold

49

out of 100

Grade: D+

Growth: 8.0Profit: 5.5Value: 4.0Quality: 5.5
Piotroski: 5/9Altman Z: 1.69

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APGSignificantly Overvalued (-23.3%)

Margin of Safety

-23.3%

Fair Value

$36.50

Current Price

$44.67

$8.17 premium

UndervaluedFair: $36.50Overvalued
VRTXUndervalued (+56.0%)

Margin of Safety

+56.0%

Fair Value

$973.13

Current Price

$427.65

$545.48 discount

UndervaluedFair: $973.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Revenue GrowthGrowth
15.3%8/10

15.3% revenue growth

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$108.71B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

APG2 concerns · Avg: 3.5/10
Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Profit MarginProfitability
4.0%3/10

4.0% margin — thin

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.084/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : APG

The strongest argument for APG centers on EPS Growth, Revenue Growth. Revenue growth of 15.3% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : APG

The primary concerns for APG are Altman Z-Score, Profit Margin. Thin 4.0% margins leave little buffer for downturns.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

APG profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

APG carries more volatility with a beta of 1.69 — expect wider price swings.

APG is growing revenue faster at 15.3% — sustainability is the question.

VRTX generates stronger free cash flow (349M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 49/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Api Group Corp

INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA

APi Group Corporation provides security, specialty and industrial services primarily in North America. The company is headquartered in New Brighton, Minnesota.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?